FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954020213> ?p ?o ?g. }

• W2954020213 abstract "The chromosomal rearrangements of the mixed-lineage leukemia gene MLL (KMT2A) have been extensively characterized as a potent oncogenic driver in leukemia. For its oncogenic function, most MLL-fusion proteins exploit the multienzyme super elongation complex leading to elevated expression of MLL target genes. High expression of MLL target genes overwrites the normal hematopoietic differentiation program, resulting in undifferentiated blasts characterized by the capacity to self-renew. Although extensive resources devoted to increased understanding of therapeutic targets to overcome de-differentiation in ALL/AML, the inter-dependencies of targets are still not well described. The majority of inhibitors potentially interfering with MLL-fusion protein driven transformation have been characterized in individual studies, which so far hindered their direct cross-comparison. In our study, we characterized head-to-head clinical stage inhibitors for BET, DHODH, DOT1L as well as two novel inhibitors for CDK9 and the Menin-MLL interaction with a focus on differentiation induction. We profiled those inhibitors for global gene expression effects in a large cell line panel and examined cellular responses such as inhibition of proliferation, apoptosis induction, cell cycle arrest, surface marker expression, morphological phenotype changes, and phagocytosis as functional differentiation readout. We also verified the combination potential of those inhibitors on proliferation and differentiation level. Our analysis revealed significant differences in differentiation induction and in modulating MLL-fusion target gene expression. We observed Menin-MLL and DOT1L inhibitors act very specifically on MLL-fused leukemia cell lines, whereas inhibitors of BET, DHODH and P-TEFb have strong effects beyond MLL-fusions. Significant differentiation effects were detected for Menin-MLL, DOT1L, and DHODH inhibitors, whereas BET and CDK9 inhibitors primarily induced apoptosis in AML/ALL cancer models. For the first time, we explored combination potential of the abovementioned inhibitors with regards to overcoming the differentiation blockage. Our findings show substantial diversity in the molecular activities of those inhibitors and provide valuable insights into the further developmental potential as single agents or in combinations in MLL-fused leukemia." @default.
• W2954020213 created "2019-07-12" @default.
• W2954020213 creator A5007802195 @default.
• W2954020213 creator A5009242861 @default.
• W2954020213 creator A5020529398 @default.
• W2954020213 creator A5029670475 @default.
• W2954020213 creator A5037661286 @default.
• W2954020213 creator A5061973032 @default.
• W2954020213 creator A5090829768 @default.
• W2954020213 date "2019-06-28" @default.
• W2954020213 modified "2023-10-12" @default.
• W2954020213 title "Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia" @default.
• W2954020213 cites W1502629510 @default.
• W2954020213 cites W1560166507 @default.
• W2954020213 cites W1607484210 @default.
• W2954020213 cites W163145306 @default.
• W2954020213 cites W1945032888 @default.
• W2954020213 cites W1970309962 @default.
• W2954020213 cites W1985807840 @default.
• W2954020213 cites W1990356011 @default.
• W2954020213 cites W1995451068 @default.
• W2954020213 cites W1998142511 @default.
• W2954020213 cites W2008183573 @default.
• W2954020213 cites W2034066489 @default.
• W2954020213 cites W2041212323 @default.
• W2954020213 cites W2042725548 @default.
• W2954020213 cites W2069918359 @default.
• W2954020213 cites W2082592723 @default.
• W2954020213 cites W2089348996 @default.
• W2954020213 cites W2091208410 @default.
• W2954020213 cites W2104910696 @default.
• W2954020213 cites W2105740818 @default.
• W2954020213 cites W2108498698 @default.
• W2954020213 cites W2115921217 @default.
• W2954020213 cites W2119747629 @default.
• W2954020213 cites W2121910267 @default.
• W2954020213 cites W2129129812 @default.
• W2954020213 cites W2151718828 @default.
• W2954020213 cites W2154218976 @default.
• W2954020213 cites W2157646587 @default.
• W2954020213 cites W2171482205 @default.
• W2954020213 cites W2276477110 @default.
• W2954020213 cites W2299219969 @default.
• W2954020213 cites W2330148258 @default.
• W2954020213 cites W2346815884 @default.
• W2954020213 cites W2520159331 @default.
• W2954020213 cites W2533641274 @default.
• W2954020213 cites W2551737782 @default.
• W2954020213 cites W2584347108 @default.
• W2954020213 cites W2587240909 @default.
• W2954020213 cites W2592787461 @default.
• W2954020213 cites W2617353563 @default.
• W2954020213 cites W2741876450 @default.
• W2954020213 cites W2759969772 @default.
• W2954020213 cites W2789081184 @default.
• W2954020213 cites W2794686490 @default.
• W2954020213 cites W2799870037 @default.
• W2954020213 cites W2802129476 @default.
• W2954020213 cites W2890762495 @default.
• W2954020213 cites W2916162780 @default.
• W2954020213 cites W4211173018 @default.
• W2954020213 cites W4241093998 @default.
• W2954020213 cites W4246697467 @default.
• W2954020213 doi "https://doi.org/10.1186/s13045-019-0749-y" @default.
• W2954020213 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6599250" @default.
• W2954020213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31253180" @default.
• W2954020213 hasPublicationYear "2019" @default.
• W2954020213 type Work @default.
• W2954020213 sameAs 2954020213 @default.
• W2954020213 citedByCount "20" @default.
• W2954020213 countsByYear W29540202132020 @default.
• W2954020213 countsByYear W29540202132021 @default.
• W2954020213 countsByYear W29540202132022 @default.
• W2954020213 countsByYear W29540202132023 @default.
• W2954020213 crossrefType "journal-article" @default.
• W2954020213 hasAuthorship W2954020213A5007802195 @default.
• W2954020213 hasAuthorship W2954020213A5009242861 @default.
• W2954020213 hasAuthorship W2954020213A5020529398 @default.
• W2954020213 hasAuthorship W2954020213A5029670475 @default.
• W2954020213 hasAuthorship W2954020213A5037661286 @default.
• W2954020213 hasAuthorship W2954020213A5061973032 @default.
• W2954020213 hasAuthorship W2954020213A5090829768 @default.
• W2954020213 hasBestOaLocation W29540202131 @default.
• W2954020213 hasConcept C104317684 @default.
• W2954020213 hasConcept C111829193 @default.
• W2954020213 hasConcept C123894998 @default.
• W2954020213 hasConcept C127716648 @default.
• W2954020213 hasConcept C148738053 @default.
• W2954020213 hasConcept C150194340 @default.
• W2954020213 hasConcept C2778461978 @default.
• W2954020213 hasConcept C2779634854 @default.
• W2954020213 hasConcept C40767141 @default.
• W2954020213 hasConcept C41091548 @default.
• W2954020213 hasConcept C502942594 @default.
• W2954020213 hasConcept C54355233 @default.
• W2954020213 hasConcept C62112901 @default.
• W2954020213 hasConcept C74401373 @default.
• W2954020213 hasConcept C86803240 @default.
• W2954020213 hasConcept C95444343 @default.
• W2954020213 hasConceptScore W2954020213C104317684 @default.

• next